Analysts at Maxim Group initiated coverage on shares of Omeros Corp (NASDAQ: OMER) in a research report issued to clients and investors on Tuesday. The firm set a “buy” rating and a $23.00 price target on the stock.
Several other analysts have also recently commented on the stock. Analysts at WBB Securities raised their price target on shares of Omeros Corp from $10.50 to $20.00 in a research note to investors on Thursday, March 22nd. They now have a “strong-buy” rating on the stock. Separately, analysts at Canaccord Genuity upgraded shares of Omeros Corp from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, March 14th. They now have a $13.00 price target on the stock, up previously from $5.00. Finally, analysts at Wedbush reiterated an “outperform” rating on shares of Omeros Corp in a research note to investors on Tuesday, March 13rd.
Shares of Omeros Corp traded down 2.35% during mid-day trading on Tuesday, hitting $9.15. Omeros Corp has a one year low of $3.16 and a one year high of $10.88. The company’s market cap is $205.3 million.
Omeros Corporation, is a clinical-stage biopharmaceutical company. It is engaged in discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system.